ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Copenhagen University Hospital
Copenhague, DinamarcaPublicaciones en colaboración con investigadores/as de Copenhagen University Hospital (11)
2020
-
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Cancer discovery, Vol. 10, Núm. 2, pp. 198-213
2019
-
A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer
ESMO Open, Vol. 4, Núm. 4
-
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
European Journal of Cancer, Vol. 123, pp. 146-154
2018
-
Integration of oncology and palliative care: a Lancet Oncology Commission
The Lancet Oncology, Vol. 19, Núm. 11, pp. e588-e653
-
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
Investigational New Drugs, Vol. 36, Núm. 5, pp. 848-859
-
Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii154-viii155
-
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from the prospective, observational CORRELATE study
Annals of Oncology, Vol. 29, pp. v104
2017
-
Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity
Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5406-5415
-
Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, pp. iii10
2016
-
First-in-human phase i study of lumretuzumab, a glycoengineered humanized anti-HER3 monoclonal antibody, in patients with metastatic or advanced HER3-positive solid tumors
Clinical Cancer Research, Vol. 22, Núm. 4, pp. 877-885
2011
-
A phase 3 trial of bevacizumab in ovarian cancer
New England Journal of Medicine, Vol. 365, Núm. 26, pp. 2484-2496